The widespread adoption of AI in prior authorization is now a policy objective, driven by the current administration's focus on efficiency and cost reduction in Medicare. The WISeR program, a CMS demonstration project launched this year (2026), will serve as a critical test case for how AI tools integrate into existing healthcare reimbursement structures. Expectations are high for AI to reduce administrative burdens and accelerate approvals for routine procedures, but there is also a clear risk of increased denials, particularly for complex or nuanced cases that AI models may misinterpret. This tension means the industry can expect ongoing debate, further studies, and potentially new regulatory guidance as the real-world impact of these systems becomes clearer. The experience of patients and providers with these AI-driven systems will largely shape public and political sentiment moving forward. We are entering a phase where the theoretical benefits of AI will confront the messy realities of healthcare delivery and patient advocacy.
Image: courtesy of Ars Technica
AI's Double-Edged Promise: Will It Streamline Prior Authorization or Supercharge Denials?
The Trump administration and the Centers for Medicare and Medicaid Services (CMS) are pushing for broader use of artificial intelligence (AI) to reform prior authorization protocols, particularly through a new pilot program called WISeR. The goal is to reduce waste and fraud and expedite approvals for "unambiguously allowable claims." However, healthcare providers and patient advocates express significant concerns, citing evidence from a 2024 Senate committee report and a 2025 American Medical Association survey suggesting AI tools could drastically increase wrongful denials, potentially by as much as 16 times. The central tension is whether AI will truly fix a historically problematic system or simply automate and amplify its existing flaws, leading to greater access barriers for patients.
Outlook
Background
Prior authorization, a bureaucratic hurdle requiring healthcare providers to secure insurer approval before rendering certain treatments or medications, has long been a source of profound friction within the American healthcare system. While initially conceived as a mechanism to curb unnecessary procedures and manage costs, its execution has frequently resulted in significant treatment delays, an escalating administrative burden for clinicians, and widespread frustration for patients caught in the middle. The depth of this sentiment is not new: a 2025 American Medical Association (AMA) survey of physicians revealed considerable resistance to the notion of AI-driven prior authorization, signaling a pervasive skepticism within the medical community about its genuine benefit.
The current impetus for integrating AI into these protocols stems directly from the Trump administration. Its stated aim is to ameliorate prior authorization processes, aligning with broader governmental objectives of reducing waste and fraud in federal healthcare programs. This policy direction has materialized tangibly through the Centers for Medicare and Medicaid Services (CMS) WISeR (Wasteful and Inappropriate Service Reduction) Model. Launched this year (2026), WISeR is a demonstration project specifically designed to deploy AI in original Medicare. Its core mandate is to identify and curb waste and fraud, with the explicit goal of decreasing procedures deemed unnecessary.
Advocates for AI integration champion its analytical prowess. They argue that AI's capacity to rapidly process and interpret vast datasets could fundamentally streamline the approval pathway for claims that are "unambiguously allowable." This suggests that for routine procedures or straightforward diagnoses, AI could cut through red tape, accelerating approvals and reducing the current backlog. The industry itself appears receptive, with insurance companies collectively representing 80% of the American public having "voluntarily agreed" to explore AI solutions to address existing wait times. Their motivation is clear: leveraging AI to pinpoint "fraud" and "overuse" could lead to substantial efficiency gains and cost savings.
Yet, this optimistic outlook is shadowed by substantial concerns. A 2024 Senate committee report, a key document frequently cited by the AMA, presented troubling findings, accusing AI tools of generating care denial rates that were, in some instances, 16 times higher than those seen with traditional methods. These figures are not anecdotal; they represent a data-driven challenge to the notion that AI will inherently improve patient access. Furthermore, researchers at Stanford have issued their own warnings, outlining specific risks associated with delegating health coverage decisions to AI. These risks extend beyond mere statistical anomalies. They encompass the potential for AI models to inadvertently inherit and amplify historical biases embedded within the data they are trained on. This could lead to a systemic increase in automated wrongful denials, creating new, technologically reinforced barriers for patients seeking medically necessary care. The fundamental challenge, therefore, is to reconcile the compelling promise of administrative efficiency with the paramount importance of patient safety, equitable access, and clinical judgment. The technology's potential for good is undeniable, but so too is its capacity to entrench and scale existing systemic flaws.
Precedents
The healthcare industry has a deeply ingrained history of turning to technological innovation as a panacea for its complex administrative and financial challenges. Each wave of new tools, from the initial rollout of electronic health records (EHRs) to sophisticated automated billing and coding systems, has arrived with the promise of unprecedented efficiency and cost control. The reality, however, has often been a more nuanced blend of progress and unforeseen complications. Early EHRs, for example, were heralded as the solution to fragmented patient information and poor care coordination. While they did centralize data, they also introduced new forms of administrative overhead, contributing to physician burnout through excessive data entry and creating persistent interoperability hurdles that continue to plague the system.
A more direct parallel to the current AI debate can be found in the evolution of automated claims processing. Decades ago, initial attempts to streamline insurance claims often resulted in what many providers termed "denial mills." These systems, relying on rigid rule sets, would frequently reject claims for minor coding discrepancies or incomplete documentation, irrespective of medical necessity. This mechanical approach necessitated a vast increase in manual appeals and rework, effectively shifting the administrative burden from the payer's initial review process to the provider's back office. The cycle was clear: efficiency for one party often translated into increased workload and frustration for another, all while delaying patient access to care.
What distinguishes the current integration of AI, particularly advanced machine learning, from these earlier iterations of automation is its scale, its inherent complexity, and crucially, the often-opaque nature of its decision-making. Traditional rule-based systems operate on explicit, transparent logic: if X, then Y. AI models, by contrast, learn intricate patterns from vast datasets, developing predictive capabilities that can be incredibly powerful but also notoriously difficult for humans to fully trace or audit. This phenomenon, often referred to as the "black box" problem, raises profound questions about accountability. If an AI system denies a patient life-saving treatment, how does one challenge a decision whose underlying logic is not readily decipherable? This lack of transparency undermines the ability of patients and providers to effectively appeal wrongful denials, potentially eroding trust in the entire system.
Historically, the introduction of new technologies aimed at cost containment in healthcare has rarely resulted in a net reduction of administrative burden across the board. Instead, it frequently reconfigures and displaces that burden. The challenge now is whether AI will transcend this pattern, delivering genuine, system-wide efficiency that benefits all stakeholders, or if it will merely accelerate the existing cycle, making the process faster but not necessarily fairer, more transparent, or more accurate in its ultimate impact on patient care. The institutional limitations and entrenched interests within healthcare suggest that any technological solution, no matter how advanced, will inevitably confront these deep-seated structural realities.
The integration of artificial intelligence into prior authorization is far more than a mere technical upgrade; it represents a profound, potentially transformative shift in the fundamental mechanisms by which access to medical care is determined for millions of Americans. For patients, the consequences are intensely personal and often dire. Delays in receiving necessary treatments, or outright denials of care, particularly for critical or chronic conditions, can lead to a cascade of negative outcomes: worsening health, prolonged suffering, and immense financial and emotional distress. If AI systems, as suggested by the concerning data from the Senate committee report and the AMA survey, lead to a substantial increase in wrongful denials, the human cost could be staggering. This automation could erect a new, technologically sophisticated barrier between individuals and the essential medical interventions they require, potentially exacerbating existing health inequities if algorithmic biases are allowed to persist.
For healthcare providers, including physicians and their administrative staff, the implications are equally significant. Prior authorization is already a leading contributor to physician burnout, diverting an estimated hours each week — precious clinical time — away from direct patient care and into bureaucratic paperwork. If AI systems introduce even more intricate appeal processes, or if they generate a higher volume of denials that demand manual review and intervention, it risks further straining an already overstretched workforce. The resolute stance of the American Medical Association, specifically their objection to AI-enabled tools that "automatically deny more and more needed care," underscores the deep-seated concern within the medical community. Their fear is that this technological shift could erode clinical autonomy, marginalize physician expertise, and ultimately compromise the bedrock principle that medical decisions should remain patient-centric and physician-led, not algorithmically dictated.
From an economic standpoint, the allure of AI is its promise to significantly reduce the billions of dollars currently consumed annually by the administrative overhead of prior authorization, while simultaneously curbing waste and fraud. Should these systems prove genuinely effective, the theoretical benefits could include lower healthcare premiums, more efficient allocation of resources, and a more sustainable healthcare economy. However, this optimistic economic calculus hinges on a critical condition: that these efficiency gains do not come at the unacceptable cost of denying medically necessary care. If the legal, reputational, and administrative expenses associated with managing a surge of appeals, public outcry, and potential litigation—not to mention the societal cost of poorer health outcomes—outweigh the savings from automated denials, then the economic advantages could prove entirely illusory. The delicate equilibrium between controlling healthcare costs and ensuring equitable patient access is a perpetual, defining challenge of the American system. AI now stands at the very fulcrum of this equation, possessing the power to either rebalance it towards greater efficiency and equity or to tip it further out of alignment, with far-reaching consequences for the entire nation's health and economic well-being.
Scenarios
Analysis1. Streamlined Efficiency with Enhanced Oversight: One possible outcome is that AI systems, particularly through carefully managed pilot programs like the CMS WISeR Model, could mature into genuinely effective tools that significantly reduce administrative burdens while maintaining, or even improving, the accuracy of prior authorization decisions. This would necessitate a multi-faceted approach: AI models would need continuous refinement, trained on diverse and unbiased datasets, and designed with explicit safeguards against wrongful denials. Crucially, this scenario would likely involve a hybrid model where AI handles the initial, high-volume screening of straightforward claims, automatically approving those that are unambiguously allowable. However, any claim flagged for potential denial or requiring complex clinical judgment would be automatically escalated for review by human clinicians. This approach would leverage AI's speed for efficiency while preserving human oversight for nuanced cases. Robust regulatory frameworks would be essential, mandating transparency in AI algorithms, requiring regular audits of denial rates, and establishing clear, accessible appeal processes for patients and providers. If successful, this could lead to a net reduction in healthcare costs by more effectively targeting waste and fraud, while simultaneously reducing treatment delays and physician burnout for routine procedures.
2. Escalation of Denials and Patient Access Barriers: A more pessimistic, yet plausible, outcome is that the widespread deployment of AI in prior authorization could exacerbate the very problems it aims to solve. If AI models are primarily optimized for aggressive cost containment and trained on historical claims data that inherently contains biases towards denial, they could lead to a substantial and systemic increase in wrongful denials. The 2024 Senate committee report's finding of AI tools producing denial rates up to 16 times higher than typical serves as a stark warning. In this scenario, patients would face significantly greater hurdles in accessing medically necessary care, leading to prolonged treatment delays, worsening health conditions, and increased out-of-pocket costs as they navigate complex appeal processes. Healthcare providers would be caught in an escalating cycle of administrative work, spending more time challenging automated denials than delivering care, further contributing to burnout and eroding the patient-provider relationship. This outcome could disproportionately impact vulnerable populations or those with rare or complex conditions that AI algorithms, lacking human empathy and contextual understanding, might misinterpret or dismiss. The resulting public outcry and political pressure would almost certainly trigger a wave of reactive, potentially heavy-handed, regulatory interventions.
3. Dynamic Regulatory Landscape and Evolving Standards: Irrespective of whether AI ultimately proves to be a net positive or negative, its integration into prior authorization will undeniably usher in a period of intense regulatory scrutiny and constant evolution of industry standards. As real-world data emerges from programs like WISeR and from private insurer implementations, policymakers and regulatory bodies like CMS will be compelled to respond. If concerns about patient harm or systemic denial increases persist, new legislation may be enacted to mandate greater algorithmic transparency, require human-in-the-loop oversight, or establish more robust and equitable appeal mechanisms. Regulators could also begin to set specific performance benchmarks for AI-driven prior authorization systems, potentially tying reimbursement to adherence to these standards, or even imposing penalties for excessive wrongful denials. This outcome suggests that the current phase is merely the beginning of a prolonged and iterative process. The "rules of the road" for AI in healthcare coverage are far from settled; they will be continuously shaped by technological advancements, real-world outcomes, patient advocacy, and the ever-present tension between cost control and quality of care. The legal and ethical frameworks around AI accountability, particularly in life-or-death decisions, are still nascent and will likely develop rapidly in response to these deployments.
Timeline
Frequently Asked Questions
Discussion
Be the first to share your thoughts.